Journal
INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES
Volume 22, Issue 23, Pages -Publisher
MDPI
DOI: 10.3390/ijms222312987
Keywords
Alzheimer's disease; amyloid beta; G-protein-coupled receptors; nicotinic acetylcholine receptors; N-methyl D-aspartate receptors; gamma-aminobutyric acid (GABA)
Funding
- Infectious Disease Society of America
Ask authors/readers for more resources
Despite the identification of A beta plaques and NFTs as biomarkers for AD pathology, therapeutic interventions for AD remain elusive. Current treatments focus on symptomatic relief, but the complexity of AD pathology requires a wide range of therapeutic approaches for prevention and cure.
Despite the identification of A beta plaques and NFTs as biomarkers for Alzheimer's disease (AD) pathology, therapeutic interventions remain elusive, with neither an absolute prophylactic nor a curative medication available to impede the progression of AD presently available. Current approaches focus on symptomatic treatments to maintain AD patients' mental stability and behavioral symptoms by decreasing neuronal degeneration; however, the complexity of AD pathology requires a wide range of therapeutic approaches for both preventive and curative treatments. In this regard, this review summarizes the role of receptors as a potential target for treating AD and focuses on the path of major receptors which are responsible for AD progression. This review gives an overall idea centering on major receptors, their agonist and antagonist and future prospects of viral mimicry in AD pathology. This article aims to provide researchers and developers a comprehensive idea about the different receptors involved in AD pathogenesis that may lead to finding a new therapeutic strategy to treat AD.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available